Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIV-1-Infection”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00038480
What this trial is testing

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 31
Not applicableNot Yet RecruitingNCT06247527
What this trial is testing

Psychoeducation, Relaxation, PrOblem Solving, Activation, Cognitive Coping Therapy for Adolescents and Youth in HIV Care

Who this might be right for
Depression, AnxietyTraumaHIV-1-infection
University of Nairobi 600
Testing effectiveness (Phase 2)Study completedNCT02251223
What this trial is testing

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

Who this might be right for
HIV Infections
Boehringer Ingelheim 208
Not applicableStudy completedNCT01446718
What this trial is testing

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

Who this might be right for
Human PapillomavirusHIV-1 Infection
Kenya Medical Research Institute 179
Not applicableStudy completedNCT00002173
What this trial is testing

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

Who this might be right for
HIV Infections
The Immune Response Corporation
Testing effectiveness (Phase 2)Ended earlyNCT00824369
What this trial is testing

A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Who this might be right for
HIV-1
Pfizer 52
Large-scale testing (Phase 3)Study completedNCT01939197
What this trial is testing

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Who this might be right for
Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis C+1 more
AbbVie 318
Not applicableStudy completedNCT01048671
What this trial is testing

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

Who this might be right for
HIV Infections
Merck Sharp & Dohme LLC 482
Testing effectiveness (Phase 2)Study completedNCT00008463
What this trial is testing

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Who this might be right for
HIV InfectionsHepatitis C
National Institute of Allergy and Infectious Diseases (NIAID) 132
Large-scale testing (Phase 3)Active Not RecruitingNCT04255849
What this trial is testing

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Who this might be right for
HPV Positive Oropharyngeal Squamous Cell CarcinomaHIV-1-infectionHPV Infection
Weill Medical College of Cornell University 700
Not applicableLooking for participantsNCT07563309
What this trial is testing

Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test

Who this might be right for
HIV 1 InfectionHIV 2 InfectionSyphilis Infection+1 more
bioLytical Laboratories 1,000
Not applicableStudy completedNCT00002398
What this trial is testing

Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

Who this might be right for
HIV Infections
Gilead Sciences
Early research (Phase 1)Study completedNCT00124007
What this trial is testing

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 114
Post-approval studies (Phase 4)Study completedNCT00718536
What this trial is testing

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

Who this might be right for
HIV Infections
Germans Trias i Pujol Hospital 15
Testing effectiveness (Phase 2)Study completedNCT01092104
What this trial is testing

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

Who this might be right for
HIV-1 Infection
Tobira Therapeutics, Inc. 52
Early research (Phase 1)Study completedNCT00712530
What this trial is testing

Single DermaVir Immunization in HIV-1 Infected Patients on HAART

Who this might be right for
HIV Infection
Genetic Immunity 9
Not applicableStudy completedNCT01074931
What this trial is testing

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

Who this might be right for
HIV-1 Infections
Abbott 98
Large-scale testing (Phase 3)Study completedNCT03311945
What this trial is testing

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

Who this might be right for
HIV InfectionsHIV-1-infectionHIV Seropositivity
Judit Pich 33
Early research (Phase 1)Study completedNCT00000977
What this trial is testing

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 52
Early research (Phase 1)UnknownNCT01881581
What this trial is testing

Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS

Who this might be right for
Acquired Immunodeficiency Syndrome
Centers for Disease Control and Prevention, China 56
Next Page